tirzepatide in type 1 diabetes Effect of on Body Weight and Control Adults With Diabetes and Overweight or Obesity Tirzepatide: A Promising Drug for

CVS Caremark negotiated a deal with Novo Nordisk (Wegovy's manufacturer) that made Wegovy the preferred GLP-1 medication starting July 2025

Advertisement China GLP-1 drug study suggests slim chance weight stays off after treatment Significant weight returned weeks after stopping drug, say researchers who advise patients to adjust expectations 2-MIN READ2-MIN 1 A Chinese analysis of prescription anti-obesity medications has added to evidence that people who use popular GLP-1 drugs such as Ozempic to shed pounds face the prospect of significant weight rebound once they stop using them challenges similar to those presented by more traditional slimming strategies

Results Baseline characteristics seem to determine the treatment choice Patient characteristics are shown in Table 1

The published trials used standard escalation schedules

Protein Drug Stability: A Formulation Challenge